Close menu




DEFENCE THERAPEUTICS INC

Photo credits: pixabay.com

Commented by André Will-Laudien on February 9th, 2022 | 12:22 CET

MorphoSys, Defence Therapeutics, Valneva, CureVac - Find the bio blockbuster!

  • Biotechnology

The biotech sector is a highly dynamic growth market within the equity universe. It is characterized by investment volumes of unprecedented size, which is also the reason for the high innovation rate characteristic of the sector. Price reactions to positive or negative surprises can be very volatile, and these tendencies are often exacerbated by the intervention of stop orders or the occurrence of derivative slippage. Vaccine manufacturers were down over 50% across the board, as the pandemic is being traded as a phase-out. The vaccination rate does not appear to be increasing significantly. Where are the opportunities for investors at the moment?

Read

Commented by Armin Schulz on January 31st, 2022 | 13:31 CET

BioNTech, Defence Therapeutics, Mainz Biomed - After Corona, cancer is the next hype

  • Biotechnology

The euphoria surrounding vaccine manufacturers has come to an end. The majority of investors believe that the end of the pandemic is near with Omicron. More and more states are abandoning restrictions and slowly returning to normalcy. If that happens, one of the biggest hypes of the last decade will come to an end. The pharmaceutical and biotech industries have earned very well from it. After the hype is before the hype. The next big story is cancer, and there are more and more cancer cases, so fighting the disease is a lucrative business. A lot is happening in this area, so we are looking at three companies today.

Read

Commented by Nico Popp on January 25th, 2022 | 10:15 CET

BioNTech, Defence Therapeutics, Nordex: Investors must pay attention here!

  • Biotechnology

"Defying cancer" was the headline of the Frankfurter Allgemeine Zeitung a few days ago. The interview was illustrated with the two leading BioNTech heads, Özlem Türeci and Uğur Şahin. The famous German scientists' statement revolved around further projects for BioNTech and the fight against cancer. At the same time, BioNTech's stock, like many other pandemic winners, dropped. What does this mean for investors now?

Read

Commented by Carsten Mainitz on January 20th, 2022 | 12:14 CET

Evotec, Defence Therapeutics, Formycon - Who will benefit from Omicron?

  • Biotechnology

The Coronavirus has shown that without biotechnology and ongoing research, we are relatively defenseless against the whims of nature. What would have happened if novel technology had not been available to produce potent vaccines in a very short time? Would our intensive care units have been as crowded as they were in Italy at the beginning of the pandemic? Would hospital triage be the norm today? No one can say for sure, but history has shown how epidemics - such as the Spanish flu - have claimed many lives in the past.

Read

Commented by Stefan Feulner on January 14th, 2022 | 11:44 CET

BioNTech, Defence Therapeutics, PAION - Seizing the momentum

  • Biotechnology

The Corona pandemic brought biotechnology to the forefront of society's consciousness, especially since the first vaccines were created in German laboratories. However, the biotech spectrum is much broader than pandemic vaccine research. In addition to research in medicine, the sector is playing an increasingly important role in environmental protection, agriculture and the ongoing climate change.

Read

Commented by André Will-Laudien on December 28th, 2021 | 07:15 CET

BioNTech, Pfizer, Defence Therapeutics, Valneva - The Corona year 2022 is coming

  • Biotechnology

The German government has moved its goal of vaccinating 80% of the population against the coronavirus at least once into the new year. The targeted quota is now to be achieved by the end of January, a government spokesman told the press. The background is that only 73.4% of the population has been vaccinated so far, and the missing 5.3 million first-time vaccinations could hardly be achieved by January 7. The interim goal of 30 million vaccinations by the end of the year, on the other hand, will most likely be met after Christmas, government sources say. The general vaccination obligation is to come on the agenda of the Federal Parliament in the first meeting week in the new year. Thus also the year 2022 will stand under the star "Corona". The following shares are part of the orchestra.

Read

Commented by Carsten Mainitz on December 8th, 2021 | 12:53 CET

Pfizer, Defence Therapeutics, Novavax - Who will benefit from Omicron?

  • Biotechnology

The world is trembling before the new Corona variant Omicron. Stock exchanges are going down, panic reigns in the crypto markets and politicians are outbidding each other with calls for tighter lockdown regulations. However, some experienced epidemiologists already see the emergence of Omicron as an indication of an imminent change from pandemic to endemic, in which we will live with the Coronavirus as if it were the flu. However, everyone agrees on one thing: we will still need vaccination. Who is this good news for?

Read

Commented by Stefan Feulner on December 3rd, 2021 | 12:38 CET

BioNTech, Defence Therapeutics, QIAGEN - End in sight?

  • Biotechnology

The federal and state governments have met and decided on a de facto lockdown for the unvaccinated. In the future, only vaccinated and recovered people will be allowed to shop in retail stores. The same applies to cinemas, theaters and restaurants. In addition, the unvaccinated will have to accept contact restrictions. According to the outgoing chancellor, this is an "act of national solidarity" and is necessary to get out of the current difficult situation - hard times, which the Omicron variant has just exacerbated. But according to US strategists, it is precisely the newly emerged mutant that could signal the approaching end of the Corona pandemic.

Read

Commented by Nico Popp on November 24th, 2021 | 12:41 CET

BioNTech, Defence Therapeutics, Novavax: Another step towards vaccination against cancer

  • Biotechnology

In Portugal and Spain, vaccination rates are higher than in Germany. There are various discussions about the reasons for this. One argument is the fact that infant mortality was high in both countries for a long time. Those who still vividly remember the stories of dead or lifelong damaged infants are less likely to think twice when the doctor calls for vaccination. The recent experience with BioNTech and other vaccines could also give a new boost to the willingness to vaccinate. It is, therefore, quite fitting that vaccines against many different diseases are now emerging on the market.

Read

Commented by Armin Schulz on November 3rd, 2021 | 11:03 CET

MorphoSys, Defence Therapeutics, Formycon - Biotech and pharma offer potential for the portfolio

  • Biotechnology

The pharmaceutical industry alone has annual sales of over EUR 1,000 billion worldwide and helps people overcome their illnesses. Since the Corona pandemic, biotech and pharma companies are even more in the spotlight. If a company manages to develop a blockbuster, big profits also beckon to shareholders. BioNTech is currently a prime example of this, even if the share has consolidated in the meantime. Where there are high profits, there is also a higher risk. The road to the development and approval of a drug is long, and failure is also possible. As people are getting older and diseases are rising, it makes sense to invest in these areas. Today we analyze three potential candidates.

Read